Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 2Plasma cell 2Other hematologic neoplasm 2Dermatologic 2Tumor-Agnostic 1Lymphoid 1Genitourinary 1Endocrine 1Classical hematology 1CNS 1Breast 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

Docetaxel 390pembrolizumab 325Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Anti-Bacterial Agents × Genitourinary × Clear all
NCT00003824 2012-03-09

S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer

SWOG Cancer Research Network

Phase 3 Terminated
114 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡